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Of 10 variation sites between sequences of amyloid-resistant porcine islet amyloid polypeptide
(pIAPP) and amyloid-prone human IAPP (hIAPP), seven locate within residues 17–29, the most amy-
loidogenic fragment within hIAPP. To investigate how these variations affect amyloidogenicity, 26
IAPP(17–29) or IAPP(20–29) variants were synthesized and their secondary structures, amyloidoge-
nicity, oligomerization and cytotoxicity were studied. Our results indicated that pIAPP fragments
are refractory to amyloid formation and signiﬁcantly less cytotoxic compared with hIAPP fragments.
A novel stable dimer was observed in pIAPP(20–29) solution, whereas hIAPP(20–29) exists mostly as
monomers and trimers. Among all human to porcine substitutions, S20R caused the most prolonged
lag time and signiﬁcantly attenuated cytotoxicity. The different oligomerization and amyloidogenic
properties of hIAPP and pIAPP fragments are discussed.
Structured summary:
pIAPP and pIAPP bind: shown by molecular sieving (view interactions 1, 2)
hIAPP and hIAPP bind: shown by molecular sieving (view interactions 1, 2)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The formation of amyloid aggregates by human islet amyloid
polypeptide (hIAPP, also known as amylin) is regarded as a major
causative factor of type 2 diabetes (T2DM) [1]. IAPP is a 37-residue
peptide hormone synthesized by the pancreatic b-cells [2]. It has
been documented that both human and feline IAPP are prone to
form toxic aggregates, whereas IAPP from rodents such as rat
and degu are resistant to this process [3]. In an elegant recent
study, Potter et al. reported that porcine IAPP (pIAPP) is signiﬁ-
cantly less amyloidogenic compared with hIAPP, thus supporting
the potential application of porcine islet transplantation in T2DM
therapy [4]. Sequence comparison shows 10 variation sites be-
tween hIAPP and pIAPP (bold in Fig. 1). Notably, seven out of thesechemical Societies. Published by E
ﬂuoroisopropanol; IAPP, islet
-yl)-2,5-diphenyltetrazolium
olid phase peptide synthesis;
n electron-microscopy; TFE,
residues are designated by
ng), kunhuang2008@hotmail.10 sites are located within the region of residues 17–29, with ﬁve
of these being found between residues 20 and 29. These have been
suggested to be the most critical and aggregation-prone regions for
hIAPP amyloid formation [3,5,6].
To investigate how these sequence variations affect the amy-
loidogenic properties of IAPP, we studied the effects of substitut-
ing these sites with residues from the corresponding human or
porcine residues in the templates of IAPP(17–29) and IAPP(20–
29), which have been widely used as model peptide fragments
in studying the amyloid formation of IAPP [3,7]. A set of 26 IAPP
peptide fragments were chemically synthesized and their second-
ary structures, oligomerization and amyloidogenicity were tested.
Our results demonstrated that pIAPP(17–29) and pIAPP(20–29)
fragments were refractory to form amyloid aggregates, whereas
all hIAPP(20–29) or hIAPP(17–29) variants carrying single or
multiple porcine substitutions showed certain degrees of pro-
longed ﬁbrillation lag time, with an arginine substitution at posi-
tion 20 resulting in the most prolonged lag time. Furthermore,
we showed that pIAPP(20–29) forms a novel stable dimer,
whereas hIAPP(20–29) exists as monomers and trimers, implicat-
ing a potential link between oligomerization and amyloidogene-
city. Possible mechanisms on the role of oligomerization
involvement in amyloid formation are then discussed from a
structural perspective.lsevier B.V. All rights reserved.
Fig. 1. Primary sequences of hIAPP, pIAPP and rIAPP. All peptides have an amidated C terminus and a disulﬁde bridge between Cys-2 and Cys-7. Residues differing from the
human IAPP are indicated in bold.
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2.1. Materials
Synthetic hIAPP(1–37) was obtained from Genscript Inc. (Pis-
cataway, NJ, USA). All reagents for peptide synthesis were obtained
from GL Chemicals Ltd. (Shanghai, China). Hexaﬂuoroisopropanol
(HFIP) and thioﬂavin-T (ThT) were purchased from Sigma–Aldrich
(St. Louis, USA). The INS-1 cells were obtained from the China Cen-
ter for Type Culture Collection (CCTCC). All other chemicals were of
the highest grade available.
2.2. Peptide synthesis and puriﬁcation
All decapeptides (IAPP(20–29)) and tridecapeptides (IAPP(17–
29)) were manually synthesized using standard 9-ﬂuorenylmethyl
chloroformate-based solid-phase peptide synthesis (SPPS) meth-
odology as we previously described [8]. Crude peptides were puri-
ﬁed by reverse phase high performance liquid chromatography
using C4 semi-preparative or analytical column (Kromasil, Akzo-
Nobel, Netherlands), and their identities were conﬁrmed by ESI-
MS.
2.3. Far-UV circular dichroism (CD) and data analysis
The CD spectra were recorded at 25 C under a constant ﬂow
of N2 by using a JASCO-810 spectropolarimeter (Tokyo, Japan).
Data were recorded from 260 to 190 nm with a 1 mm pathlength.
Puriﬁed peptide was dissolved in 50 mM sodium phosphate buf-
fer (pH 7.4) containing 100 mM NaCl and 1% HFIP, or with 50%
triﬂuoroethanol (TFE) co-solvent. The ﬁnal peptide concentration
was 10 lM (hIAPP(1–37)) or 100 lM (all other peptides). The
spectra were recorded with a scanning speed of 20 nm/min, a re-
sponse time of 1 s and a bandwidth of 2 nm. Each result was the
average of three measurements. The data were converted to mean
residue ellipticity [h] and were further analyzed by the software
package CDPro as we and others previously described [9,10].
Two reference data sets – SDP 42 (#6) and SDP 48 (#7) – were
used in CDPro analysis since they both include denatured pro-
teins [10].
2.4. Thioﬂavin-T (ThT) ﬂuorescence assay and Aggrescan software
analysis
Puriﬁed peptides were ﬁrst dissolved in HFIP and sonicated for
2 min to homogenize the sample. The peptide solutions were fur-
ther diluted to a ﬁnal assay solution containing 50 mM sodium
phosphate, 100 mM NaCl, 2% HFIP, 16.7 lM ThT and 100 lM pep-
tide (except hIAPP, which was 20 lM), pH 7.4. The experiments
were performed on a Hitachi FL-2700 ﬂuorometer equipped with
a kinetic measurement module and a thermostat water-pump sys-
tem. The samples were incubated at 37 C in a quartz cuvette withconstant stirring at a ﬁxed rate of 800 rpm. The excitation and
emission wavelengths were set at 450 nm and 482 nm, respec-
tively. The seeding experiments (self- or cross-seeding) were
performed as we previously described [9,11]. Brieﬂy, freshly pre-
pared amyloids were sonicated for 3 min and immediately applied
to fresh sample solution at 5% (w/w) ﬁnal concentration as seeds.
All experiments were repeated at least three times. The following
formula was used to ﬁt the kinetic curves as described [12,13],
the t50 is described as time at half-maximum intensity, and the
lag time is described as t50  2/k:
Y ¼ Y0 þ ðYmax  Y0Þ=½1þ expðt  t50Þk
The amyloidogenic propensities of peptides were also predicted
with the program Aggrescan as described [14].
2.5. Transmission electronic microscopy (TEM)
The TEM was performed as we previously described [11].
Brieﬂy, 5-ll samples were applied to a 300-mesh Formvar-carbon
coated copper grid (Shanghai, China), followed by staining with 1%
fresh prepared uranyl formate, air dried and observed under a
transmission microscope (Hitachi, Tokyo, Japan) operating at accel-
erating voltages of 100 kV.2.6. Size-exclusion chromatograph (SEC)
The SEC analysis was performed on a Tosoh TSK GW2000 col-
umn (Tokyo, Japan) eluted with a 50 mM phosphate buffer con-
taining 100 mM NaCl, pH 7.2 with a ﬂow rate of 0.5 ml/min.
Bovine serum albumin, ovalbumin, hen egg-white lysozyme, tryp-
sin, RNAase A, porcine insulin, human glucagon-like peptide-1
amide (7–36) and an octapeptide (MW 854.9) were used for
molecular weight calibration.
2.7. Cell toxicity assays
INS-1 cells were cultured in phenol red-free RPMI 1640 media
containing 10% FBS, 1% sodium pyruvate and 50 lM b-mecaptoeth-
anol. The 96-well plates were coated with 0.1% gelatin before use.
The cells were plated at a density of 5  103 cells/well. Following
24-h incubation at 37 C in 5% CO2 atmosphere, fresh medium con-
taining 100- or 200-lM different peptide fragments was added and
further incubated for 24 h. Wells treated with medium containing
the same amount of PBS were used as a negative control. After
incubation, 20-ll 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) (5 mg/ml) was added to each well and
incubated for 4 h. The absorbance was then measured at 570 nm.
The average absorbance of the PBS-treated cells was set as 100%
cell viability. Each treatment was repeated at least three times.
All results were expressed as the mean ± S.D. Statistical signiﬁ-
cance was evaluated with the Kruskal–Wallis test [15], followed
Fig. 2. Far-UV CD spectroscopy of IAPP fragments. Spectra were recorded at 25 C in PBS buffer (A) or with 50% TFE (B).
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tistically signiﬁcant at P < 0.05.
3. Results
3.1. Peptide synthesis
Twenty-six IAPP peptide fragments were manually synthesized
and puriﬁed (for sequence details see Supplementary Fig. S1). Their
identities were conﬁrmed by ESI-MS (data not shown).
3.2. Secondary structures determination by far-UV CD and spectra
deconvolution
To investigate the secondary structures of peptide fragment
variants synthesized, far-UV CD spectroscopy was applied. Spectra
were recorded in PBS buffer containing 1% HFIP.1 Overall, CD spec-
tra of hIAPP(1–37) and IAPP fragments were characteristic of pre-
dominant random coil structure (Fig. 2A and Supplementary
Fig. S2), and supported by further CDPro deconvolution analysis2
(Supplementary Fig. S3 and Table S1), which agreed with the previ-
ous reports [16,17]. It is of interest to note that spectra showed mod-
est differences in the region of 210–230 nm between the hIAPP and
pIAPP fragments, where spectra of hIAPP(20–29) and hIAPP(17–29)
showed more positive CD signals than those of pIAPP(20–29) and
pIAPP(17–29) (Fig. 2A).
CD spectra were also recorded in the presence of 50% TFE
(Fig. 2B). Compared with spectra collected in PBS, further deconvo-
lution analysis suggested a greatly increased extent of secondary
structural components in 50% TFE (Supplementary Fig. S3 and Ta-
ble S2). These differences found between the spectra in 50% TFE
and PBS were, however, not as dramatic as previously reported
[18]. Spectral differences between hIAPP and pIAPP fragments
were still observed, however (Fig. 2B).
3.3. Amyloid formation
We ﬁrst examined the amyloidogenic properties of IAPP(17–29)
fragments. The ThT-binding assays suggested that under our
experimental conditions, hIAPP(17–29) readily formed typical long
linear amyloid ﬁbrils (Fig. 3) and gave strong ThT emission with a
short lag time of 39.1 ± 10.0 min (Table 1). In contrast, pIAPP(17–
29) was rather refractory to amyloid formation under testing con-1 Control experiments showed that 1% HFIP in buffer does not interfere with the
secondary structures of tested peptides (data not shown).
2 Since CDPro utilizes mostly large globular proteins in its reference data sets,
therefore analysis results for our short and highly ﬂexible IAPP peptide fragments are
subject to larger uncertainties than analysis of globular proteins.ditions, with more than 24 h constant stirring at 37 C failing to
raise ThT ﬂuorescence. Only proteinaceous pIAPP(17–29) precipi-
tates but not linear ﬁbrils were observed under TEM (Fig. 3 and Ta-
ble 1). pIAPP differs from hIAPP between residues 17 and 20 in
three sites: 17D, 18R and 20R (Fig. 1). Among these sites, 17D
and 20R exist only in porcine, whereas 18R is also present in spe-
cies like rodent, chicken and feline. To test their impacts on the
amyloidogenicity of IAPP, fourteen analogs were synthesized in
IAPP(17–29) templates (human or porcine, Supplementary
Fig. S1). Our results suggested that both 17D and 18R substitutions
show minor impacts on the ﬁbrillation of hIAPP(17–29). For
hIAPP(17–29) carrying single 17D mutation or 17D18R double
mutations, slightly lengthened lag times of 66.9 ± 12.9 min and
64.7 ± 17.5 min were observed as compared with the control
hIAPP(17–29) (39.1 ± 10.0 min) (Table 1). In contrast, 20R-hIA-
PP(17–29) showed a dramatically prolonged lag time compared
with hIAPP(17–29) (241.5 ± 114.0 min vs. 39.1 ± 10.0 min). Next,
we tested the ﬁbrillation properties of hIAPP(17–29) carrying
17D20R double substitutions or 17D18R20R triple substitutions,
in which lengthened lag times of 329.2 ± 30.7 min and
283.8 ± 88.2 min were observed (Table 1), suggesting that 20R
may play an important role in prolonging the lag time in pIA-
PP(217–229). We further applied pIAPP(17–29) as a template to
test the impact of corresponding human substitutions (17V, 18H
and 20S). Interestingly, none of these substitutions (single or com-
bined) cause amyloid formation after stirring for up to 8 h at 37 C
(Table 1 and Supplementary Fig. S4).
We next synthesized nine IAPP(20–29) analogs and tested how
ﬁve additional variant sites (Fig. 1) may affect the amyloidogenic-
ity in the IAPP(20–29) template. ThT-ﬂuorescence and TEM assays
suggested that hIAPP(20–29) readily gave strong ThT ﬂuorescence
emission and formed long-linear amyloid ﬁbrils with a short lag
time of 39.6 ± 15.7 min (Fig. 3 and Table 1). Conversely, no positive
ThT emission or ﬁbrils were observed for pIAPP(20–29) even after
agitation for more than 30 h (Fig. 3 and Table 1). Fibrillation of four
hIAPP(20–29) analogs carrying single porcine substitution (20R,
23L, 25T and 27F) was also examined.3 Our results suggested that
the ﬁbrillation lag times of analogs 20R-, 23L-, 25T- and 27F-hIA-
PP(20–29) fell in the order of 20R > 27F > 25T > 23L (Table 1), in
which the 20R-hIAPP(20–29) analog showed a drastic 10-fold pro-
longed lag time (401.4 ± 116.4 min vs. 39.6 ± 15.7 min), which was
in good accord with what we observed in the IAPP(17–29) samples.
For position 20, amyloidogenecity of glycine and lysine substitutions
was also examined. ThT assays showed that 20G-hIAPP(20–29)3 We were unable to synthesize enough 29P-hIAPP(20–29) analogue for assays,
however, based on previous studies by Westermark et al. [3], 29P-hIAPP(20–29)
shows similar amyloidogenic property as hIAPP(20–29), but is relatively slow in
forming amyloids.
Fig. 3. Amyloidogenic properties of IAPP fragments as monitored with ThT ﬂuorescence and TEM. (A) ThT-ﬂuorescence of selected hIAPP fragments and pIAPP fragments; (B)
seeding assays of hIAPP(20–29), 20R-hIAPP(20–29) and pIAPP(20–29); and (C)–(F) TEM images of hIAPP(1–37) (C), hIAPP(20–29) (D), 20R-hIAPP(20–29) (E) and pIAPP(20–
29) (F).
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vs. 39.6 ± 15.7 min), whereas 20 K substitution results in a 7-fold in-
crease in lag time (288.2 ± 24.4 min vs. 39.6 ± 15.7 min). However,
no direct correlations were identiﬁed between experimentally mea-
sured lag times and the software Aggrescan predicted values (Table
1).
Next, seeding experiments were performed for samples hIA-
PP(20–29), pIAPP(20–29) and 20R-hIAPP(20–29). Results sug-
gested that 5% freshly prepared hIAPP(20–29) seed signiﬁcantly
shortened the lag phase of itself (Table 1), which agreed with the
previous report [19]. On the contrary, hIAPP(20–29) seed failed
to induce pIAPP(20–29) amyloid formation even after co-incuba-
tion for 8 h (Fig. 3B). However, hIAPP(20–29) seed did promote
the ﬁbrillation of 20R-hIAPP(20–29) (lag time 181.5 ± 90.1 min
vs. 401.4 ± 116.4 min, Fig. 3B). On the other hand, although 5%
freshly prepared 20R-hIAPP(20–29) seed shortened the ﬁbrillation
lag time of itself (184.6 ± 32.2 min vs. 401.4 ± 116.4 min, Fig. 3B), it
failed to promote the ﬁbrillation of hIAPP(20–29) (lag time
65.6 ± 3.9 min vs. 39.6 ± 15.7 min).
3.4. Peptide oligomerization studied by SEC
To investigate the oligomerization of IAPP fragments, SEC
experiments were performed. In freshly prepared hIAPP(20–29)
sample (HFIP- and sonication-treated), a relatively small trimer
peak (20.1 min) followed by a large monomer peak (21.2 min)
was observed, whereas in pIAPP(20–29), a dimer peak (20.5 min)
was identiﬁed as the major peak, with no obvious monomer or tri-
mer peak being identiﬁed. It is of interest to note that 20R-hIA-
PP(20–29) showed an intermediate SEC proﬁle between that of
pIAPP(20–29) and hIAPP(20–29), with a major monomeric peak
(21.2 min) being found to coexist with a small dimer shoulder
(20.6 min) (Fig. 4). However, in all three decapeptide fragments,
a similar hexamer peak (18.9 min) was found (Fig. 4).
Further SEC-monitored kinetics studies indicated markedly
different oligomerization proﬁles during ﬁbrillization of both hIA-PP(20–29) and pIAPP(20–29). In hIAPP(20–29), a gradually dimin-
ishing trimer peak coupled with an ascending hexamer peak was
observed as the incubation time increased (Supplementary
Fig. S5). On the other hand, in pIAPP(20–29) samples, the dimer
peak remain unchanged during the incubation, which is consistent
with our ThT observation (Supplementary Fig. S5).
3.5. Cell viability assays
The aggregation of hIAPP(1–37) and its fragments, including
hIAPP(17–29) and hIAPP(20–29), has been reported to exhibit
cytotoxicity [4,18,20]. MTT assay was used to investigate the cyto-
toxicity of IAPP fragment variants in INS-1 cells. In our study, the
hIAPP(1–37) at 20 lM exhibited a 75% toxic effect. At a concentra-
tion of 200 lM, hIAPP(20–29) and hIAPP(17–29) exhibited toxic
effects of 40% and 31%, respectively, the highest in both the deca-
peptide and tridecapeptide sample groups, whereas pIAPP(20–29)
and pIAPP(17–29) only showed 16% and 21% cytotoxicity, respec-
tively, giving the lowest cytotoxicity in both groups. Moreover,
our results clearly suggested that the 20R substitution signiﬁcantly
reduced the toxicity of hIAPP fragments (17% vs. 40% for decapep-
tide, and 21% vs. 31% for tridecapeptide, Fig. 5). Varied degrees of
cytotoxicity were also observed for the rest of the decapeptide
and tridecapeptide variants (Supplementary Figs. S8 and S9). How-
ever, at 100 lM concentration, hIAPP fragments (hIAPP(17–29) and
hIAPP(20–29)) were only slightly more toxic compared with pIAPP
fragments (pIAPP(17–29) and pIAPP(20–29)) (Fig. 5 and Supple-
mentary Fig. S8).
4. Discussion
Not all species develop islet amyloid in vivo [3,21,22]. Rat IAPP
(rIAPP) is well-known for amyloid-resistance. It has been sug-
gested that hIAPP(17–29), especially the 20–29 region, is the major
fragment for the formation of toxic hIAPP amyloid deposits [3]. The
sequences of rIAPP and hIAPP differ at six of 37 positions, all
Table 1
Amyloidogenic properties of peptide fragments.a
Peptides Substitution(s) Fibril formationb
Predictionc Lag time (min) t50 (min) Amyloidogenicd
Human 1–37e  5.6 0 ± 0 27.2 ± 20.7 +++
17–29  1.0 39.1 ± 10.0 80.7 ± 28.5 +++
17–29 D17 14.8 66.9 ± 12.9 83.0 ± 4.4 ++
17–29 D17, R18 16.1 64.7 ± 17.5 69.4 ± 15.2 ++
17–29 D17, R18, R20 24.8 283.8 ± 88.2 370.7 ± 119.2 +
17–29 D17, R20 23.5 329.2 ± 30.7 406.7 ± 29.6 +
17–29 R20 7.7 241.5 ± 114.0 335.0 ± 179.6 +++
20–29  10.8 39.6 ± 15.7 64.3 ± 15.6 +++
20–29 R20 5.2 401.4 ± 116.4 429.3 ± 117.2 ++
20–29 G20 9.4 12.5 ± 3.6 25.5 ± 12.6 +++
20–29 K20 7.0 288.2 ± 24.7 390.7 ± 80.1 +
20–29 F27 14.6 252.9 280.0 +
20–29 T25 6.4 73.6 ± 43.5 121.4 ± 66.9 +++
20–29 L23 9.6 73.6 ± 43.5 121.4 ± 66.9 +++
Porcine 17–29  25.9 1440+  
17–29 V17 10.1 500+  
17–29 H18 24.7 500+  
17–29 V17,H18 8.8 500+  
17–29 V17,H18,S20 0.1 500+  
17–29 V17,S20 1.4 500+  
17–29 H18,S20 15.9 500+  
17–29 S20 17.2 500+  
20–29  3.0 2400+  
20–29 S20 8.6 500+  
Cat 20–29  6.1 184.2 ± 43.7 245.3 ± 51.8 +
17–29  2.3 104.0 ± 81.6 147.0 ± 90.6 ++
17–29 H18 1 48.9 ± 14.0 122.8 ± 57.8 ++
Seeding hIAPP(20–29) seeded with hIAPP(20–29) 15.7 ± 5.3 50.3 ± 22.1 +++
20R-hIAPP(20–29) seeded with 20R-hIAPP(20–29) 184.6 ± 32.2 226.0 ± 41.3 ++
20R-hIAPP(20–29) seeded with hIAPP(20–29) 181.5 ± 90.1 240.0 ± 95.4 +++
pIAPP(20–29) seeded with hIAPP(20–29) 500+  
hIAPP(20–29) seeded with 20R-hIAPP(20–29) 65.6 ± 3.9 89.3 ± 1.3 +++
a All assays were repeated for at least three times except 27F-hIAPP(20–29), which was performed for once due to limited sample supply.
b All samples were studied at 100 lM concentration except hIAPP(1–37), which was studied at 20 lM.
c Prediction values were calculated with the program Aggrescan [13], peptides are less prone to form amyloid with lower values [13].
d Semi-quantitative analysis of ThT-ﬂuorescence based amyloid formation: ‘‘+++’’ designates samples with ﬂuorescence intensity change greater than 40 arbitrary units,
‘‘++’’ for values between 10 and 40 arbitrary units, ‘‘+’’ for values between 1 and 10 arbitrary units, and ‘‘’’ for values less than 0.1 arbitrary units.
e hIAPP(1–37) shows zero lag time in our assays, which may due to the fast stirring and high salt concentration used in the assay.
Fig. 4. Size-exclusion gel ﬁltration proﬁles of different IAPP(20–29) fragments.
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studies have been carried out to investigate how these variations
affect amyloidogenicity, and two proline residues (25P and 28P)
have been suggested to play more critical roles than 18H, 23L,
26V and 29P in resisting amyloid-formation [3]. Surprisingly, ithas been reported that a single arginine to histidine substitution
at position 18 abolishes the amyloid-resistant property of rIAPP
and renders this variant capable of forming ﬁbrils [23]. Full-length
pIAPP has recently been reported to be refractory to amyloid for-
mation [4]. Interestingly, the region of residues 17–29 also hosts
seven out of 10 variation sites (Fig. 1), suggesting the important
role this region played in amyloidogenic determination. Here, we
demonstrated for the ﬁrst time that both pIAPP(17–29) and
pIAPP(20–29) were resistant to form amyloid in vitro under phys-
iological conditions and that these fragments were also signiﬁ-
cantly less cytotoxic compared with the corresponding human
fragments. Of all single-substitutions tested, we found each por-
cine substitution caused certain degrees of delayed lag time, but
none of them could abolish the ﬁbrillation of hIAPP(17–29) or hIA-
PP(20–29). On the other hand, none of the human substitutions
(single or combined) could cause pIAPP(20–29) or pIAPP(17–29)
fragments to gain amyloidogenic properties, which is different
from the previous report that single human substitutions like
R18H, L23F and V26I could cause amyloid-formation in rIAPP
[23]. Thus, we conclude that the amyloidogenic properties of pIAPP
and hIAPP are due to the combined effects of multiple site
substitutions.
Of special interest, we identiﬁed position 20 as a critical site in
determining the amyloidogenicity. Position 20 has been reported
to relate to an inheritable T2DM which is mostly identiﬁed in Asia
and Africa [24–26]. It has been reported that a 20G mutation could
Fig. 5. Cell viability determined by MTT assay. (A) Cytotoxicity of IAPP(20–29) fragments at concentrations of 100 lM and 200 lM. (B) Cytotoxicity of IAPP(17–29) fragments
at concentrations of 100 lM and 200 lM. Peptides are as labeled. 20 lM hIAPP(1–37) was used as the positive control.
Fig. 6. Postulated role of oligomerization in the formation of mature IAPP(20–29)
amyloid.
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cord with our observations on 20G-hIAPP(20–29). Moreover, the
facts that the 20R substitution caused the most prolonged lag time
and greatly attenuated the cytotoxicity of hIAPP further suggest
the importance of this site in determining the propensity of
amyloidogenic and cytotoxicity. Furthermore, the signiﬁcantly
prolonged lag time of the control analog 20K-hIAPP(20–29) sug-
gested that the positive charge and/or the bulky side-chain may
place a barrier to the assembly of amyloid aggregates.
The oligomerization states of IAPP and related fragments have
been studied mostly by molecular dynamics simulation and exper-
imental evidence is still necessary [29–31]. The present gel ﬁltra-
tion study revealed different oligomerization properties of
fragments of hIAPP and pIAPP. In hIAPP(20–29), monomeric, tri-
meric and a small amount of hexameric forms were observed,
and the kinetic assay suggested that as the ﬁbrillation went on,
the trimer population starts diminishing while the population of
higher molecular weight oligomers (mostly hexamers) gradually
increases (Supplementary Fig. S5). However, in the corresponding
pIAPP fragments, a major dimer peak was found, which remain
essentially unchanged during incubation (Fig. 4 and Supplemen-
tary Fig. S5), suggesting that this dimer may be quite stable in solu-
tion. Similarly, the observation that the oligomerization proﬁle of
20R-hIAPP(20–29) lies between that of pIAPP(20–29) and hIA-
PP(20–29) suggested that the 20R substitution may disrupt the tri-
mer assembly and favor the formation of both dimers and
monomers. To our knowledge, this is the ﬁrst report that proved
the existence of hIAPP(20–29) trimers, although its existence has
been predicted by in silico molecular dynamics simulations [30].
On the other hand, we were unable to identify a hIAPP(20–29) di-
mer as another molecular dynamics simulation study suggested
[31]. The existence of pIAPP(20–29) dimers has not been reported.
We speculate that the intermolecular forces that stabilize this di-
mer may be critical to the prolonged ﬁbrillation lag times. It has
been reported by Raleigh et al. that rIAPP exists in solution as a
monomer [32], indicating that pIAPP(20–29) may gain its ﬁbril-
resisting capacity with a novel dimer-forming mechanism.
Although the exact spatial structure of hIAPP amyloid remains
unknown, accumulating structural evidence suggests that hIAPP
molecule may adapt a b-hairpin like structure in the protoﬁbril
as well as in mature ‘‘cross-b’’ amyloid ﬁbrils, in which residue
20 is located in the middle of the b-turn [33]. In support of thisidea, a recent study on hIAPP and rIAPP demonstrated that the
aggregation-prone hIAPP forms intramolecular b-turn more readily
than rIAPP [34]. Techniques including X-ray ﬁber diffraction, elec-
tron diffraction, cryo-EM, FTIR, solid-state NMR and molecular
dynamics simulations have been intensively applied to determine
the ﬁbril structure of hIAPP fragments, for example hIAPP(20–
29), hIAPP(21–27), hIAPP(28–33) [20,35–37], with all results sug-
gesting that the amyloidogenic region 20–29 adopts a steric zipper
structure and further forms the cross-b spine of hIAPP amyloid
[38]. Based on these observations, we proposed a possible amy-
loid-resistance mechanism for pIAPP in which the formation of sta-
ble dimers prevents peptides from further assembling into the b-
turn structure and also the formation of the following nucleus
and ordered mature ﬁbrils (Fig. 6).
Peptide fragment-based hIAPP inhibitors have been previously
constructed with good inhibitory effects [6,39,40]. It will also be
of future interest to study the possibility of developing pIAPP
X. Zhang et al. / FEBS Letters 585 (2011) 71–77 77sequences based on hIAPP amyloid inhibitors and explore their po-
tential therapeutic usages in T2DM.
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